Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1/2 study of DS-3939a in advanced solid tumors
jRCT2031230233Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of DS-3939 in advanced nonhematological malignancy, Metastatic solid neoplasm, Nonhematologic neoplasms and 1 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicities (DLT), Adverse events (AEs) and 2 more. Started Aug 2023; status: recruiting.
02
Drugs
DS-3939
03
Conditions
advanced nonhematological malignancyMetastatic solid neoplasmNonhematologic neoplasmsprostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031230233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230233.